Alumis Inc. (ALMS)

Alumis and ACELYRIN amended their proposed merger pact, with Acelyrin's stock gaining after Trium Capital rebuffed the deal. Alumis filed a $400 million mixed securities shelf. The company completed patient enrollment in the LUMUS Phase 2b trial of ESK-001 for Systemic Lupus Erythematosus and announced an update on a Phase 1 clinical study for ESK-001. Alumis reported its Q2 results, missing revenue expectations. Analysts made substantial upgrades to Alumis Inc.'s forecasts. Alumis participated in investor conferences. ALMS stock had risen by 6.42% compared to the previous week and 20.25% over the last month, though it showed a -59.92% decrease over the last year.

There is no information available to suggest demand seasonality for Alumis, Inc.'s products or services. Demand for its products is typically driven by disease prevalence, diagnosis rates, and the efficacy and availability of treatments, rather than seasonal fluctuations.

Alumis, Inc. is a biopharmaceutical company focused on developing therapies for autoimmune diseases. The company's pipeline includes ESK-001 (envudeucitinib) for plaque psoriasis and SLE, A-005 for neuroinflammatory and neurodegenerative diseases, and Lonigutamab for thyroid eye disease. Alumis integrates research, partnerships, and a patient-centric approach, generating revenue through product sales, licensing, and research funding.

Alumis, Inc. is headquartered in San Francisco, California. Its clinical trials, such as the LUMUS Phase 2b trial for ESK-001, are global.

Alumis, Inc. maintains a generally positive brand reputation, particularly within the investment community, as evidenced by analyst ratings. The company has received a consensus rating of "Moderate Buy" and "Very Bullish" from Wall Street analysts. The company's mission to "transform treatment for immune-mediated diseases" and its "precision approach" leveraging data analytics contribute to its brand identity as an innovative and patient-focused biopharmaceutical firm.

Alumis Inc. has a diverse ownership structure comprising institutional, retail, and individual investors. Major institutional owners include Ayurmaya Capital Management Company, LP, Foresite Capital Management V, LLC, Samsara BioCapital, LLC, venBio Partners LLC, Foresite Capital Management VI LLC, BlackRock, Inc., Vanguard Group Inc, Trium Capital LLP and Nextech Invest, Ltd. Institutional investors hold approximately 15.43% of the company's stock, insiders hold 68.52%, and public companies and individual investors hold 16.04%. Another breakdown indicates that retail investors own 38%, institutions 26%, and hedge funds 21%, with insiders owning less than 1%. Foresite Labs, LLC owns the most shares of Alumis Inc.